Cite
Supplementary Methods from Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
MLA
Geoffrey R. Oxnard, et al. Supplementary Methods from Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3222331f9df0def6140f62b8dd62ce6d&authtype=sso&custid=ns315887.
APA
Geoffrey R. Oxnard, Alexander Drilon, S. Michael Rothenberg, Pasi A. Jänne, Marc Ladanyi, Barry S. Taylor, Lynette M. Sholl, Bob T. Li, Jaclyn F. Hechtman, Kevin Ebata, Morana Vojnic, Jenna E. Scanlon, Elizabeth A. Olek, Binoj C. Nair, Marina S.D. Milan, Mika Lin, Elaine M. Kelley, Dahlia N. Henry, Elena V. Ivanova, … Ezra Y. Rosen. (2023). Supplementary Methods from Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Chicago
Geoffrey R. Oxnard, Alexander Drilon, S. Michael Rothenberg, Pasi A. Jänne, Marc Ladanyi, Barry S. Taylor, Lynette M. Sholl, et al. 2023. “Supplementary Methods from Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3222331f9df0def6140f62b8dd62ce6d&authtype=sso&custid=ns315887.